Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2014

View Archived Issues

Visual acuity improvement seen in interim results from squalamine eye drops trial

Optimization of a GPR40 agonist for type 2 diabetes

Aurigene and Orion form BET bromodomain collaboration

Nandrolone decanoate/vitamin D3 fixed-dose combination evaluated in multiple doses

Roche and Ferring collaborate on personalized female infertility treatment

Johnson & Johnson and Dana-Farber Cancer Institute establish lung cancer collaboration

DART Therapeutics changes name

Targacept begins phase I/II study of TC-6499 in diabetic gastroparesis

GSK begins phase III study of eltrombopag in myelodysplastic syndromes

Aerie Pharmaceuticals reports phase IIb results for Roclatan

Novel neurogenesis-stimulating agents disclosed by Roche

Roche divulges novel MSP receptor agonists

Bayer patent describes potential hemophilia treatments

BioMarin Pharmaceutical discloses new fusion protein for LSD

Japanese researchers present radiation-induced injury treatments

HerpV vaccine shows significant reduction in viral burden

Coronado Biosciences reports topline results from investigator-initiated pilot study

NovaBiotics begins phase IIa study of Lynovex in cystic fibrosis

Eisai submits first MAA for anticancer agent lenvatinib in Japan

Boehringer Ingelheim's idarucizumab receives FDA breakthrough therapy designation

Basilea initiates phase IIa trial of BAL-101553

Nora Therapeutics begins phase II study of NT-100 in women with recurrent pregnancy loss

Phase II results reported on refametinib in patients with pancreatic cancer

Aurinia initiates phase IIb trial of voclosporin in lupus nephritis

Cancer stemness kinase inhibitor BBI-503 tested in patients with advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...